News
ATYR
4.080
-18.24%
-0.910
Weekly Report: what happened at ATYR last week (1109-1113)?
Weekly Report · 2d ago
Weekly Report: what happened at ATYR last week (1102-1106)?
Weekly Report · 11/09 09:09
aTyr Pharma Files Prospectus for Potential Stock Sales
TipRanks · 11/06 21:32
aTyr Pharma Files ~$80M At-The-Market Offering To Sell Common Stock Through Jefferies
Benzinga · 11/06 21:14
aTyr Pharma downgraded to Hold from Buy at Freedom Broker
TipRanks · 11/06 20:30
Analysts Have Conflicting Sentiments on These Healthcare Companies: CytomX Therapeutics (CTMX), Rezolute (RZLT) and aTyr Pharma (ATYR)
TipRanks · 11/06 19:40
aTyr Pharma Is Maintained at Sector Perform by RBC Capital
Dow Jones · 11/06 19:35
aTyr Pharma Price Target Cut to $6.00/Share From $40.00 by RBC Capital
Dow Jones · 11/06 19:35
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $6
Benzinga · 11/06 19:26
aTyr Pharma Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 11/06 14:47
aTyr Pharma Price Target Raised to $4.00/Share From $1.00 by Wells Fargo
Dow Jones · 11/06 14:47
Wells Fargo Maintains Equal-Weight on aTyr Pharma, Raises Price Target to $4
Benzinga · 11/06 14:38
aTyr: FDA Alignment Offers Upside, but Prior Trial Failure and Partnering Risk Warrant Caution
TipRanks · 11/06 13:57
aTyr Pharma price target lowered to $35 from $280 at Piper Sandler
TipRanks · 11/06 12:22
aTyr Pharma GAAP EPS of -$7.43 misses by $3.43
Seeking Alpha · 11/05 22:35
aTyr Pharma reports Q3 EPS ($7.43), consensus ($4.00)
TipRanks · 11/05 21:28
aTyr Pharma Q3 EPS $(7.43) Misses $(4.00) Estimate
Benzinga · 11/05 21:25
Press Release: aTyr Pharma Announces Third -2-
Dow Jones · 11/05 21:01
Press Release: aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
Dow Jones · 11/05 21:01
Atyr Pharma: Q3 Earnings Snapshot
Barchart · 11/05 15:26
More
Webull provides a variety of real-time ATYR stock news. You can receive the latest news about Atyr Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).